Please find enclosed herewith Outcome of Board Meeting held today i.e. 21st May, 2025. Kindly take the note of the same and acknowledge.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.9 pts less than Nifty Microcap 250 and 5.0 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Daikaffil Chemicals India Ltd's board met on May 21, 2025 and approved audited financial results for Q4 and FY ended March 31, 2025. Total income for FY25 stood at ₹796.60 lakhs versus just ₹71.11 lakhs in FY24, driven by revenue from operations of ₹749.75 lakhs (essentially nil in the prior year), indicating a major operational ramp-up. Despite the revenue growth, the company posted a net loss of ₹158.93 lakhs in FY25 (marginally improved from a ₹190.22 lakhs loss in FY24) as total expenses of ₹956.87 lakhs outpaced revenue. Cash flow from operations swung sharply negative to ₹(629.93) lakhs in FY25 (vs ₹591.82 lakhs inflow in FY24), weighed down by a steep build-up in trade receivables (₹606 lakhs) and inventory (₹325 lakhs). The board also appointed GMJ & Associates as Secretarial Auditor for five years (FY26–FY30) and SPSJ & Associates LLP as Internal Auditor for FY26. The statutory auditor, Natvarlal Vepari & Co LLP, issued an unmodified opinion on the results.
The stock remains loss-making even as revenue scales up, and the sharp swing to negative operating cash flow signals working-capital stress from rising receivables and inventory. Shareholders should watch for margin improvement and better cash conversion before considering the operational turnaround credible.